CRISPR Therapeutics AG (BKK:CRSP03)

Market Cap	171.36B +51.7%
Revenue (ttm)	133.91M -90.6%
Net Income	-18.55B
EPS	-200.85
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,940
Average Volume	21,289
Open	3.440
Previous Close	3.500
Day's Range	3.240 - 3.440
52-Week Range	2.920 - 3.880
Beta	n/a
RSI	52.44
Earnings Date	May 11, 2026

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 393
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: CRSP03

Financial Performance

In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.

Financial numbers in USD